SHANGHAI, China, Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has received approval to list its common stock on the Nasdaq Global Market.
China-Biotics expects to begin trading on the Nasdaq on October 23, 2008, until which time its common stocks will continue to trade on the Over the Counter Bulletin Board. The trading symbol for China-Biotics' common stock will remain "CHBT."
"We are extremely proud to be approved to list on the Nasdaq Global Market," said Mr. Jinan Song, China-Biotics' Chairman and Chief Executive Officer. "This upgrade to a prestigious senior exchange is a significant milestone for China-Biotics' growth as a public company. We believe Nasdaq is well suited for high-technology and high-growth companies like ours. With this milestone achieved, we hope to further enlarge our investor base and increase both our liquidity and visibility in the investment community."
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company"), a leading
manufacturer of biotechnology products and supplements, engages in the
research, development, marketing and distribution of probiotics dietary
supplements. Through its wholly owned subsidiary, Shanghai Shining
Biotechnology Co., Ltd., the Company has operations in Shanghai. Its
proprietary product portfolio contains live microbial nutritional
supplements under the "Shining" brand. Currently, the products are sold OTC
through large distributors to pharmacies and supermarkets in Shanghai,
Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand
retail outlets in major cities in China. Currently, China-Biotics is
strategically expanding its production capacity of probiotics to meet
growing demand in the bulk additive market. For more
|SOURCE China-Biotics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved